The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients
- 677 Downloads
The prodrug cyclophosphamide is metabolized by cytochrome P450(CYP)2B6 to the active metabolite, 4-hydroxycyclophosphamide (4-OH), and by CYP3A4/5 to toxic chloracetaldehyde and 2-dechloroethylcyclophosphamide (DCE). Since aprepitant is a moderate inhibitor of CYP3A4, the study was designed to determine whether its concurrent use alters the pharmacokinetics (PK) of cyclophosphamide. In addition, we sought to determine the effect of race and pharmacogenomics on cyclophosphamide PK.
Eighteen patients with localized breast cancer were randomized in this double-blinded cross-over study to receive aprepitant or placebo in addition to cyclophosphamide 600 mg/m2 and doxorubicin 60 mg/m2. Blood samples were collected for both PK analysis of cyclophosphamide and metabolites and pharmacogenomic analysis. Single nucleotide polymorphisms genotyped were CYP3A4*1B, CYP3A5*3, and CYP2B6*6.
The geometric mean area under concentration–time curve (AUC0−t μg/mL h) for cyclophosphamide was 282 following aprepitant and 230 following placebo (ratio 1.23; 90% CI 1.13, 1.33). 4-OH AUC0−t (μg/mL h) was 6.80 following aprepitant and 6.96 following placebo (ratio 0.98; 90% CI 0.88, 1.08). DCE AUC0−t (μg/mL h) was 6.76 following aprepitant and 9.37 following placebo (ratio 0.72; 90% CI 0.64, 0.81). Genotype analysis was confounded by race. Race was a significant predictor of DCE lnAUC0−t (P = 0.0169) as African Americans had approximately a 2-fold higher DCE AUC than Caucasians.
Aprepitant altered the exposure of cyclophosphamide and DCE but not the active 4-OH metabolite, making it unlikely that aprepitant would change the clinical efficacy of cyclophosphamide. African Americans were also found to have altered PK compared with Caucasian patients.
KeywordsAprepitant Cyclophosphamide Pharmacokinetics Pharmacogenomics
The authors thank Celeste Lindley, Pharm.D. for her support with study design. This study was supported by Merck Pharmaceuticals and by the General Clinical Research Centers Program of Division of Research Resources, National Institutes of Health (RR00046).
- 2.Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830PubMedCrossRefGoogle Scholar
- 3.Aprepitant product information. Merck and Company, Inc., Whitehouse Station; May 2003Google Scholar
- 6.Cyclophosphamide product information. Bristol-Myers Squibb Company, Princeton, Nov 2003Google Scholar
- 8.Roy P, Yu LJ, Crespi CL, Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655–666PubMedGoogle Scholar
- 15.Bubalo JS, Cherala G, McCune JS et al (2011) Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol, published online Mar 15, 2011Google Scholar
- 26.Lang CC, Kinirons MT, Robin DR et al (1996) Evidence of increased CYP3A4 activity in African Americans. Clin Pharm Ther 59:158 (abstract 01-B1)Google Scholar
- 29.Han HS, Reis I, Kuroi K et al (2009) Racial differences in acute toxicities of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 27(suppl; abstract e11515)Google Scholar